Search Result

Results for "

terminus

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amino Acid Derivatives (1) Aryl Hydrocarbon Receptor (1) Bacterial (3) Bcl-2 Family (1) Biochemical Assay Reagents (9) Casein Kinase (1) Complement System (3) DNA/RNA Synthesis (2) Endogenous Metabolite (3) Gap Junction Protein (2) GCGR (2) Guanylate Cyclase (1) Histone Methyltransferase (1) iGluR (2) Liposome (23) MARCKS (1) Na+/K+ ATPase (2) Neurokinin Receptor (2) Neuropeptide Y Receptor (2) Oxytocin Receptor (3) p97 (1) PD-1/PD-L1 (2) PIN1 (1) PKC (1) Polo-like Kinase (PLK) (1) RABV (1) STAT (1) Tau Protein (1) TGF-beta/Smad (1) VEGFR (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (6) Endocrinology (3) Infection (4) Inflammation/Immunology (11) Metabolic Disease (5) Neurological Disease (16)
Oligonucleotides:	Pegylated Lipids (23)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3102

GLP-1(32-36)amide	GCGR	Metabolic Disease
GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .

HY-18619

YL-109 2 Publications Verification	Aryl Hydrocarbon Receptor	Cancer
YL-109 is an antitumor agent that can induce carboxyl terminus of Hsp70-interacting protein (CHIP) expression through aryl hydrocarbon receptor (AhR) signaling. YL-109 has ability to inhibit breast cancer cell growth and invasiveness .

HY-P1884

LL-37, acetylated,amidated	Bacterial	Infection
LL-37, acetylated, amidated is a cathelicidin peptide LL-37 acetylated on the N-terminus and amidated on the C-terminus. The single human cathelicidin peptide LL-37 has antimicrobial and anti-biofilm activity against multiple Gram-positive and Gram-negative human pathogens, and has wound-healing effects on the host .

HY-P2842

Aminopeptidase	Others	Others Cancer
Aminopeptidase catalyzes the cleavage of amino acids from the amino terminus of protein or peptide substrates .

HY-131800

3'-Deoxy-3'-amino-ATP	Others	Metabolic Disease
3'-Deoxy-3'-amino-ATP, an ATP analogue, is a potent and competitive inhibitor of ATP, with a K_i of 2.3 μM. 3'-Deoxy-3'-amino-ATP can be used to synthesis of 3′-Amino-3′-deoxy transfer RNA by incorporation into the 3' terminus of tRNA-C-C .

HY-P3102A

GLP-1(32-36)amide TFA	GCGR	Metabolic Disease
GLP-1(32-36)amide TFA, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide TFA could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

HY-E70368

Collagenase G (Recombinant)	Biochemical Assay Reagents	Others
Collagenase G Recombinant is involved in the islet isolation process, and digests specific collagens from the N-terminus, especially Col-V .

HY-136887

Arphamenine B hemisulfate	Others	Others
Arphamenine B (hemisulfate) is a Zn ²⁺-dependent exopeptidase that selectively removes arginine and/or lysine residues from the NH2-terminus of several peptide substrates. Arphamenine B (hemisulfate) Arphamenine B (hemisulfate) is an inhibitor of aminopeptidase B that can be isolated from bacteria. Arphamenine B (hemisulfate) enhances the immune response and is used to characterize novel proteases .

HY-P1505

C3a (70-77) Complement 3a (70-77)	Complement System	Inflammation/Immunology
C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.

HY-108729

Tripeptidyl aminopeptidase Cerliponase alfa	Endogenous Metabolite	Neurological Disease
Tripeptidyl aminopeptidase (Cerliponase alfa) removes tripeptides from the free NH, terminus of longer peptides. Tripeptidyl aminopeptidase has the potential for the research of CLN2 disease .

HY-P1505A

C3a (70-77) (TFA) 1 Publications Verification Complement 3a (70-77) (TFA)	Complement System	Inflammation/Immunology
C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a .

HY-P3891

Substance P (4-11)	Neurokinin Receptor	Neurological Disease
Substance P (4-11), the C-terminus fragment of Substance P (Substance P (HY-P0201)), is a Substance P agonist that shows highly selective for NK1 receptors .

HY-P5007

Copeptin (human)	Biochemical Assay Reagents	Cardiovascular Disease
Copeptin (human) is a diagnostic and prognostic biomarker for cardiovascular disease (CVD). Copeptin (human) is also the carboxyl terminus of the arginine vasopressin (AVP) precursor peptide. Copeptin (human) can be used in the study of cardiovascular disease .

HY-107091

Aspartyl-alanyl-diketopiperazine DA-DKP	Others	Inflammation/Immunology
Aspartyl-alanyl-diketopiperazine (DA-DKP) is an immunomodulatory molecule generated by cleavage and cyclization from the N-terminus of human albumin and can modulate the inflammatory immune response through a molecular pathway implicated in T- lymphocyte anergy .

HY-P3932

[Sar4] Substance P (4-11)	Neurokinin Receptor	Neurological Disease
[Sar4] Substance P (4-11) is an analog of Substance P (4-11). Substance P (4-11), the C-terminus fragment of Substance P (Substance P (HY-P0201)), is a Substance P agonist .

HY-19738

NQTrp	Tau Protein	Neurological Disease
NQTrp, an aromatic naphthoquinone-tryptophan hybrid molecule, an inhibitor of the aggregation of the tau protein with generic anti-amyloidogenic effects. NQTrp inhibits the in vitro aggregation of hexapeptide ( ⁴¹GCWMLY ⁴⁶ within the N-terminus of γD-crystallin) as well as full-length γD-crystallin .

HY-W015450

D-Ala-D-Ala	Endogenous Metabolite	Others
D-Ala-D-Ala constitutes the terminus of the peptide part of the peptidoglycan monomer unit and is involved in the transpeptidation reaction as the substrate. D-Ala-D-Ala is catalyzed by D-Alanine-D-Alanine ligase. D-Ala-D-Ala is a bacterial endogenous metabolite .

HY-164166

Fmoc-Sar-Sar-Sar-OH	Biochemical Assay Reagents	Others
Fmoc-Sar-Sar-Sar-OH is a small molecule polypeptide composed of four sarcosine residues, in which the N-terminus of the peptide chain is protected by Fmoc. Fmoc-Sar-Sar-Sar-OH can be used for peptide synthesis or synthesis of drug-peptide ligand conjugates .

HY-149872

DCA-RMR1	Biochemical Assay Reagents	Others
DCA-RMR1 is a cross-linker. DCA-RMR1 elicits facile bicyclization of native peptides via N-terminus Cys-Cys cross-linking. DCA-RMR1 derivatizes RMR1 with 1,3-dichloroacetone (DCA) .

HY-P2844

Polynucleotide kinase	DNA/RNA Synthesis	Metabolic Disease
Polynucleotide Kinase is a DNA repair enzyme. Polynucleotide Kinase possesses both a 5’-kinase activity that catalyzes the transfer of phosphate from ATP to a 5’-hydroxyl (OH) terminus and also a 3’-phosphatase activity that converts 3’-phosphate termini to 3’-OH termini .

HY-157508

VCP Activator 1	p97	Others
VCP Activator 1 is a VCP activator that dose-dependently stimulates VCP ATPase activity. VCP Activator 1 binds an allosteric pocket near the C-terminus. In addition, VCP Activator 1 binding site can also be occupied by a phenylalanine residue in the VCP C-terminal tail .

HY-34738

Boc-β-Ala-ol 3-(Boc-amino)-1-propanol	Amino Acid Derivatives	Others
Boc-β-Ala-ol (3-(Boc-amino)-1-propanol) is an alanine derivative with a Boc protecting group at the N-terminus, which can be used to synthesize bioactive peptide mimics, such as Nα-Benzoyl-α-azaornithine phenyl ester, which has trypsin inhibitory activity .

HY-P1565

Transdermal Peptide Disulfide TD 1 Disulfide(peptide)	Na+/K+ ATPase	Inflammation/Immunology
Transdermal Peptide Disulfide (TD 1 Disulfide(peptide)) is a 11-amino acid peptide, binds toNa ⁺/K ⁺-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide Disulfide can enhance the transdermal delivery of many macromolecules .

HY-133513

(±)-H3RESCA-TFP (±)-H3L28	Others	Cancer
(±)-H3RESCA-TFP ((±)-H3L28) is a tetrafluorophenyl ester derivative of restrained complexing agent (RESCA). (±)-H3RESCA-TFP can be used to conjugate the chelator with a biomolecule via amine coupling (e.g., N terminus and/or the ε-amino groups of lysine) .

HY-P5439

Epsilon-V1-2, Cys-conjugated	PKC MARCKS	Others
Epsilon-V1-2, Cys-conjugated is a biological active peptide. (This peptide is the εPKC specific inhibitor. Its inhibitory activity is based on εPKC translocation and MARCKS phosphorylation. This peptide interferes with εPKC interaction with the anchoring protein εRACK. This peptide contains a cysteine residue added to the C-terminus for potential S-S bond formation with a carrier protein.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)

HY-P1565A

Transdermal Peptide Disulfide TFA TD 1 Disulfide(peptide) TFA	Na+/K+ ATPase	Others
Transdermal Peptide Disulfide TFA (TD 1 Disulfide(peptide) TFA) is a 11-amino acid peptide, binds to Na ⁺/K ⁺-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide Disulfide TFA can enhance the transdermal delivery of many macromolecules .

HY-P1116

PBP10	Bacterial	Infection Inflammation/Immunology
PBP10 is a cell permeable and selective gelsolin-derived peptide inhibitor of formyl peptide receptor 2 (FPR2) over FPR1 . PBP10 is a 10-AA peptide with rhodamine conjugated at its N terminus, exerts bactericidal activity against gram-positive and gram-negative bacteria and limits microbial-induced inflammatory effects .

HY-P1116A

PBP10 TFA 1 Publications Verification	Bacterial	Infection Inflammation/Immunology
PBP10 is a cell permeable and selective gelsolin-derived peptide inhibitor of formyl peptide receptor 2 (FPR2) over FPR1 . PBP10 is a 10-AA peptide with rhodamine conjugated at its N terminus, exerts bactericidal activity against gram-positive and gram-negative bacteria and limits microbial-induced inflammatory effects .

HY-P3815

Casein Kinase 2 Substrate Peptide 1 Publications Verification	Casein Kinase	Others
Casein Kinase 2 Substrate Peptide is a common CK2 substrate peptide. Casein Kinase 2 Substrate Peptide is synthesized with its C-terminus conjugated to 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid (EDANS). Casein Kinase 2 Substrate Peptide can be used for protein kinase CK2 activity determination .

HY-E70413

Amino acid arylamidase, hog kidney	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Amino acid arylamidase, hog kidney is a metalloprotease that can hydrolyze proteins or peptides containing free α-amino or α-imino groups, playing a crucial role in amino acid metabolism and protein digestion. Its hydrolytic activity can be blocked by acetylation of the N-terminus. Amino acid arylamidase, hog kidney can be used in research on hepatic diseases, biliary diseases, and heart failure .

HY-17573

Carbetocin 1 Publications Verification	Oxytocin Receptor	Neurological Disease Endocrinology
Carbetocin, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a K_i of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (K_i=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research. Carbetocin can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .

HY-17573A

Carbetocin acetate 1 Publications Verification	Oxytocin Receptor	Neurological Disease Endocrinology
Carbetocin acetate, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a K_i of 7.1 nM. Carbetocin acetate has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (K_i=1.17 μM). Carbetocin acetate has the potential for postpartum hemorrhage research. Carbetocin acetate can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .

HY-P3971

H-Leu-Ser-Lys-Leu-OH	TGF-beta/Smad	Inflammation/Immunology
H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis .

HY-P4086

Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R)	RABV	Infection
Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R), a chimeric peptide consisting of 29 amino acids, is synthesized by adding nona-arginine motif to the carboxy terminus of RVG (rabies virus glycoprotein). Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R) is positively charged and able to bind negatively charged nucleic acids via charge interaction .

HY-P1195

PDZ1 Domain inhibitor peptide	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P3624

Cenderitide	Guanylate Cyclase	Cardiovascular Disease
Cenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC). Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide activates both pGC-A and pGC-B, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research .

HY-P1136

Gap19	Gap Junction Protein	Cardiovascular Disease
Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial .

HY-P1195A

PDZ1 Domain inhibitor peptide TFA	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P1136A

Gap19 TFA 4 Publications Verification	Gap Junction Protein	Cardiovascular Disease
Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 TFA is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 TFA has protective effects against myocardial .

HY-P5506

C5a Receptor agonist, W5Cha	Complement System	Others
C5a Receptor agonist, W5Cha (Peptide 1) is a selective complement C5a receptor (C5aR) agonist (EC₅₀=0.2 μM), a hexapeptide derived from the C-terminus of C5a with specific amino acid modifications. C5a Receptor agonist, W5Cha is able to interact with the Arg-206 site of the C5a receptor through its C-terminal arginine, thereby activating the receptor .

HY-17573R

Carbetocin (Standard)	Oxytocin Receptor	Neurological Disease Endocrinology
Carbetocin (Standard) is the analytical standard of Carbetocin. This product is intended for research and analytical applications. Carbetocin, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a K_i of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (K_i=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research. Carbetocin can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-144012A

16:0 PEG350 PE DPPE-PEG350; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium	Liposome	Others
16:0 PEG350 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012B

16:0 PEG550 PE DPPE-PEG550; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium	Biochemical Assay Reagents Liposome	Others
16:0 PEG550 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012C

16:0 PEG750 PE DPPE-PEG750; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium	Biochemical Assay Reagents Liposome	Others
16:0 PEG750 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013A

18:0 mPEG350 PE ammonium DSPE-mPEG350 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium	Liposome	Others
18:0 mPEG350 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013B

18:0 mPEG550 PE ammonium DSPE-mPEG550 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium	Biochemical Assay Reagents Liposome	Others
18:0 mPEG550 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013C

18:0 mPEG750 PE ammonium DSPE-mPEG750 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium	Biochemical Assay Reagents Liposome	Others
18:0 mPEG750 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

Cat. No.	Product Name	Type

HY-144012A

16:0 PEG350 PE

DPPE-PEG350; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium

Drug Delivery

16:0 PEG350 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012B

16:0 PEG550 PE

DPPE-PEG550; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium

Drug Delivery

16:0 PEG550 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012C

16:0 PEG750 PE

DPPE-PEG750; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium

Drug Delivery

16:0 PEG750 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013A

18:0 mPEG350 PE ammonium

DSPE-mPEG350 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium

Drug Delivery

18:0 mPEG350 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013B

18:0 mPEG550 PE ammonium

DSPE-mPEG550 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium

Drug Delivery

18:0 mPEG550 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013C

18:0 mPEG750 PE ammonium

DSPE-mPEG750 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium

Drug Delivery

18:0 mPEG750 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012D

16:0 PEG1000 PE

DPPE-PEG1000; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium

Drug Delivery

16:0 PEG1000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012E

16:0 PEG3000 PE

DPPE-PEG3000; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium

Drug Delivery

16:0 PEG3000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012H

16:0 PEG5000 PE

DPPE-PEG5000; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium

Drug Delivery

16:0 PEG5000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013D

18:0 mPEG1000 PE ammonium

DSPE-mPEG1000 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium

Drug Delivery

18:0 mPEG1000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013E

18:0 mPEG3000 PE ammonium

DSPE-mPEG3000 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium

Drug Delivery

18:0 mPEG3000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013H

18:0 mPEG5000 PE ammonium

DSPE-mPEG5000 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium

Drug Delivery

18:0 mPEG5000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155924

14:0 PEG350 PE

DMPE-PEG350; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium

Drug Delivery

14:0 PEG350 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155925

14:0 PEG550 PE

DMPE-PEG550; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium

Drug Delivery

14:0 PEG550 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155926

14:0 PEG750 PE

DMPE-PEG750; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium

Drug Delivery

14:0 PEG750 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155927

14:0 PEG1000 PE

DMPE-PEG1000; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium

Drug Delivery

14:0 PEG1000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155928

14:0 PEG3000 PE

DMPE-PEG3000; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium

Drug Delivery

14:0 PEG3000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155929

14:0 PEG5000 PE

DMPE-PEG5000; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium

Drug Delivery

14:0 PEG5000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155930

18:1 PEG350 PE

DOPE-PEG350; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium

Drug Delivery

18:1 PEG350 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155931

18:1 PEG550 PE

DOPE-PEG550; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium

Drug Delivery

18:1 PEG550 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155932

18:1 PEG1000 PE

DOPE-PEG1000; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium

Drug Delivery

18:1 PEG1000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155933

18:1 PEG3000 PE

DOPE-PEG3000; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium

Drug Delivery

18:1 PEG3000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155934

18:1 PEG5000 PE

DOPE-PEG5000; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium

Drug Delivery

18:1 PEG5000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-N7833

Heneicosapentaenoic acid

Drug Delivery

Heneicosapentaenoic Acid (HPA) is a 21:5 omega-3 fatty acid found in trace amounts in the green alga B. pennata and in fish oils. Its chemical composition is similar to eicosapentaenoic acid (EPA), except that a carbon is extended at the carboxy terminus, placing the first double bond at the δ6 position. HPA can be used to study the importance of double bond position in omega-3 fatty acids. It incorporates phospholipids and triacylglycerols in vivo with the same efficiency as EPA and docosahexaenoic acid, and exhibits a strong inhibitory effect on the synthesis of arachidonic acid from linoleic acid. HPA is a poor substrate for prostaglandin H synthase (PGHS) (cyclooxygenase) and 5-lipoxygenase, but retains the ability to rapidly inactivate PGHS.

Cat. No.	Product Name	Target	Research Area

HY-P3102

GLP-1(32-36)amide	GCGR	Metabolic Disease
GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .

HY-P1884

LL-37, acetylated,amidated	Bacterial	Infection
LL-37, acetylated, amidated is a cathelicidin peptide LL-37 acetylated on the N-terminus and amidated on the C-terminus. The single human cathelicidin peptide LL-37 has antimicrobial and anti-biofilm activity against multiple Gram-positive and Gram-negative human pathogens, and has wound-healing effects on the host .

HY-P3102A

GLP-1(32-36)amide TFA	GCGR	Metabolic Disease
GLP-1(32-36)amide TFA, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide TFA could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .

HY-P1732

Transportan	Peptides	Cancer
Transportan is a 27 amino acid-long peptide containing 12 functional amino acids from the amino terminus of the neuropeptide galanin and mastoparan in the carboxyl terminus, connected via a lysine. Transportan belongs to cell-penetrating peptides (CPPs) .

HY-P4074

Anti-BetaGamma	Peptides	Others
Anti-BetaGamma, a peptide, is MPS-Phosducin-like protein C terminus .

HY-P1493

Fibrinopeptide B, human FPB,human	Peptides	Inflammation/Immunology
Fibrinopeptide B, human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin.

HY-P10531

ALFA-tag	Peptides	Others
ALFA-tag is a small and stable α-helical structure composed of 15 amino acids. ALFA-tag is highly hydrophilic and can be placed at the N-terminus, C-terminus, or between two independently folded domains of the target protein without affecting the function of the protein. ALFA-tag is widely used as an epitope tag and is used for the detection and manipulation of proteins in living cells .

HY-P1505

C3a (70-77) Complement 3a (70-77)	Complement System	Inflammation/Immunology
C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.

HY-P2019

Levitide	Peptides	Neurological Disease
Levitide is a neurohormone-like peptide, can be isolated from skin secretions of the South African frog Xenopus laevis. Levitide comes from preprolevitide, is 88 residues long and contains contains the levitide peptide at the C terminus (Glu-Gly-Met-Ile-Gly-Thr-Leu-Thr-Ser-Lys-Arg-Ile-Lys-Gln-NH2) and the putative signal sequence at the N terminus .

HY-P1735

Moth Cytochrome C (MCC) (88-103)	Peptides	Inflammation/Immunology
Moth Cytochrome C (MCC) (88-103), derived from the carboxyl terminus of moth cytochrome c, induces positive selection of TCR transgenic thymocytes .

HY-P2553

Histone H3 (116-136), C116-136	Peptides	Others
Histone H3 (116-136), C116-136 is a peptide spaning the C-terminus of histone H3, amino acids 116 to 136 .

HY-P10055

PSMA targeting peptide PSMA-1	Peptides	Cancer
PSMA-1 is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells.?PSMA-1 is selected and polyarginine sequences R6?or R9?were added at the C terminus to generate the CTPs. FITC labeling of the peptide with an aminohexanoic acid (Ahx) linker at the N terminus produced FITC-PSMA-1, to track PSMA binding on PCa cells .?

HY-16757

Trofinetide 1 Publications Verification NNZ-2566	Peptides	Neurological Disease
Trofinetide (NNZ-2566), a synthetic analogue of the endogenous N-terminus tripeptide, Glycine-Proline-Glutamate (GPE), has been shown to be neuroprotective in animal models of brain injury.

HY-P1493A

Fibrinopeptide B, human TFA FPB,human TFA	Peptides	Inflammation/Immunology
Fibrinopeptide B, human TFA (FPB,human TFA), human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin .

HY-P4807

Pheromone Biosynthesis Activating Neuropeptide (Helicoverpa assulta, Heliothis zea) Hez-PBAN	Peptides	Neurological Disease
Pheromone Biosynthesis Activating Neuropeptide (Helicoverpa assulta, Heliothis zea) (PBAN), a member of the PBAN/Pyrokinin neuropeptide family, characterized by a common amino acid sequence FXPRLamide motif in the C-terminus .

HY-P5954

PLTX-II	Peptides	Others
PLTX-II is a calcium channel blocker. PLTX-II has a 44-residue peptide containing ten Cys residues and an O-palmitoylated threonine amide at the carboxy-terminus .

HY-P1505A

C3a (70-77) (TFA) 1 Publications Verification Complement 3a (70-77) (TFA)	Complement System	Inflammation/Immunology
C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a .

HY-P3891

Substance P (4-11)	Neurokinin Receptor	Neurological Disease
Substance P (4-11), the C-terminus fragment of Substance P (Substance P (HY-P0201)), is a Substance P agonist that shows highly selective for NK1 receptors .

HY-P5007

Copeptin (human)	Biochemical Assay Reagents	Cardiovascular Disease
Copeptin (human) is a diagnostic and prognostic biomarker for cardiovascular disease (CVD). Copeptin (human) is also the carboxyl terminus of the arginine vasopressin (AVP) precursor peptide. Copeptin (human) can be used in the study of cardiovascular disease .

HY-P3932

[Sar4] Substance P (4-11)	Neurokinin Receptor	Neurological Disease
[Sar4] Substance P (4-11) is an analog of Substance P (4-11). Substance P (4-11), the C-terminus fragment of Substance P (Substance P (HY-P0201)), is a Substance P agonist .

HY-W015450

D-Ala-D-Ala	Endogenous Metabolite	Others
D-Ala-D-Ala constitutes the terminus of the peptide part of the peptidoglycan monomer unit and is involved in the transpeptidation reaction as the substrate. D-Ala-D-Ala is catalyzed by D-Alanine-D-Alanine ligase. D-Ala-D-Ala is a bacterial endogenous metabolite .

HY-164166

Fmoc-Sar-Sar-Sar-OH	Biochemical Assay Reagents	Others
Fmoc-Sar-Sar-Sar-OH is a small molecule polypeptide composed of four sarcosine residues, in which the N-terminus of the peptide chain is protected by Fmoc. Fmoc-Sar-Sar-Sar-OH can be used for peptide synthesis or synthesis of drug-peptide ligand conjugates .

HY-P3778

γ-Bag cell peptide	Peptides	Neurological Disease
γ-bag cell peptide is a peptide. γ-bag cell peptide is located near the N-terminus of the egg laying prohormone, the vesicle is released upon insulin stimulation. γ-bag cell peptide can be used for the research of the central and peripheral nervous systems .

HY-34738

Boc-β-Ala-ol 3-(Boc-amino)-1-propanol	Amino Acid Derivatives	Others
Boc-β-Ala-ol (3-(Boc-amino)-1-propanol) is an alanine derivative with a Boc protecting group at the N-terminus, which can be used to synthesize bioactive peptide mimics, such as Nα-Benzoyl-α-azaornithine phenyl ester, which has trypsin inhibitory activity .

HY-P1565

Transdermal Peptide Disulfide TD 1 Disulfide(peptide)	Na+/K+ ATPase	Inflammation/Immunology
Transdermal Peptide Disulfide (TD 1 Disulfide(peptide)) is a 11-amino acid peptide, binds toNa ⁺/K ⁺-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide Disulfide can enhance the transdermal delivery of many macromolecules .

HY-P5439

Epsilon-V1-2, Cys-conjugated	PKC MARCKS	Others
Epsilon-V1-2, Cys-conjugated is a biological active peptide. (This peptide is the εPKC specific inhibitor. Its inhibitory activity is based on εPKC translocation and MARCKS phosphorylation. This peptide interferes with εPKC interaction with the anchoring protein εRACK. This peptide contains a cysteine residue added to the C-terminus for potential S-S bond formation with a carrier protein.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)

HY-P1565A

Transdermal Peptide Disulfide TFA TD 1 Disulfide(peptide) TFA	Na+/K+ ATPase	Others
Transdermal Peptide Disulfide TFA (TD 1 Disulfide(peptide) TFA) is a 11-amino acid peptide, binds to Na ⁺/K ⁺-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide Disulfide TFA can enhance the transdermal delivery of many macromolecules .

HY-P10161

Ac-DMQD-pNA	Peptides	Others
Ac-DMQD-pNA is a peptide substrate. Both of the recombinant CgCaspase-1 (rCgCaspase-1) and the C-terminus of CgCaspase-1 (rCgCaspase-1-C) exhibits similar caspase activity towards proteolytic substrate Ac-DMQD-pNA and Ac-DEVD-pNA (HY-P1006) .

HY-P1116

PBP10	Bacterial	Infection Inflammation/Immunology
PBP10 is a cell permeable and selective gelsolin-derived peptide inhibitor of formyl peptide receptor 2 (FPR2) over FPR1 . PBP10 is a 10-AA peptide with rhodamine conjugated at its N terminus, exerts bactericidal activity against gram-positive and gram-negative bacteria and limits microbial-induced inflammatory effects .

HY-P1116A

PBP10 TFA 1 Publications Verification	Bacterial	Infection Inflammation/Immunology
PBP10 is a cell permeable and selective gelsolin-derived peptide inhibitor of formyl peptide receptor 2 (FPR2) over FPR1 . PBP10 is a 10-AA peptide with rhodamine conjugated at its N terminus, exerts bactericidal activity against gram-positive and gram-negative bacteria and limits microbial-induced inflammatory effects .

HY-P3815

Casein Kinase 2 Substrate Peptide 1 Publications Verification	Casein Kinase	Others
Casein Kinase 2 Substrate Peptide is a common CK2 substrate peptide. Casein Kinase 2 Substrate Peptide is synthesized with its C-terminus conjugated to 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid (EDANS). Casein Kinase 2 Substrate Peptide can be used for protein kinase CK2 activity determination .

HY-P10247

Amyloid precursor C-terminal peptide	Peptides	Neurological Disease
Amyloid precursor C-terminal peptide is cleaved from the C-terminus of Amyloid Precursor Protein (APP). Amyloid precursor C-terminal peptide accumulation causes mitochondrial morphology alteration and basal mitophagy failure, which indicates that amyloid precursor protein C-terminal peptide may correspond to an etiological trigger of Alzheimer’s disease (AD) pathology .

HY-17573

Carbetocin 1 Publications Verification	Oxytocin Receptor	Neurological Disease Endocrinology
Carbetocin, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a K_i of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (K_i=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research. Carbetocin can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .

HY-17573A

Carbetocin acetate 1 Publications Verification	Oxytocin Receptor	Neurological Disease Endocrinology
Carbetocin acetate, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a K_i of 7.1 nM. Carbetocin acetate has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (K_i=1.17 μM). Carbetocin acetate has the potential for postpartum hemorrhage research. Carbetocin acetate can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .

HY-P3971

H-Leu-Ser-Lys-Leu-OH	TGF-beta/Smad	Inflammation/Immunology
H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis .

HY-P10356

T100-Mut	Peptides	Others
T100-Mut is a cell-permeable peptide whose N-terminus is conjugated with a myristoylated group to enable T100-Mut to penetrate and localize to the inner side of the plasma membrane, thus mimicking the topology of Tmem100-3Q. T100-Mut can alleviate TRPA1-mediated pain .

HY-P4086

Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R)	RABV	Infection
Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R), a chimeric peptide consisting of 29 amino acids, is synthesized by adding nona-arginine motif to the carboxy terminus of RVG (rabies virus glycoprotein). Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R) is positively charged and able to bind negatively charged nucleic acids via charge interaction .

HY-P1195

PDZ1 Domain inhibitor peptide	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P3624

Cenderitide	Guanylate Cyclase	Cardiovascular Disease
Cenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC). Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide activates both pGC-A and pGC-B, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research .

HY-P1136

Gap19	Gap Junction Protein	Cardiovascular Disease
Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial .

HY-P1195A

PDZ1 Domain inhibitor peptide TFA	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P3727

Lys-Pro-Pro-Thr-Pro-Pro-Pro-Glu-Pro-Glu-Thr	Peptides	Inflammation/Immunology
Lys-Pro-Pro-Thr-Pro-Pro-Pro-Glu-Pro-Glu-Thr is a undecapeptide, corresponding to the carboxy terminus of simian virus 40 large T antigen. Lys-Pro-Pro-Thr-Pro-Pro-Pro-Glu-Pro-Glu-Thr can be targeted by antibodies secreted from three mouse hybridomas, designated KT1, KT3, and KT4, produced antibodies that immunoprecipitated large T antigen .

HY-P1136A

Gap19 TFA 4 Publications Verification	Gap Junction Protein	Cardiovascular Disease
Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 TFA is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 TFA has protective effects against myocardial .

HY-P5506

C5a Receptor agonist, W5Cha	Complement System	Others
C5a Receptor agonist, W5Cha (Peptide 1) is a selective complement C5a receptor (C5aR) agonist (EC₅₀=0.2 μM), a hexapeptide derived from the C-terminus of C5a with specific amino acid modifications. C5a Receptor agonist, W5Cha is able to interact with the Arg-206 site of the C5a receptor through its C-terminal arginine, thereby activating the receptor .

HY-P5509

C5aR1 antagonist peptide	Peptides	Others
C5aR1 antagonist peptide is a biological active peptide. (This linear peptide is derived from the C-terminus of the chemokine, complement fragment 5 anaphylatoxin (C5a). This peptide functions to inhibit C5a binding and function at human and rat C5a receptors. C5a is crucial to triggering cellular immune responses and its overexpression is involved in arthritis, Alzheimer’s disease, cystic fibrosis, systemic lupus erythematosus, and other immunoinflammatory diseases.)

HY-17573R

Carbetocin (Standard)	Oxytocin Receptor	Neurological Disease Endocrinology
Carbetocin (Standard) is the analytical standard of Carbetocin. This product is intended for research and analytical applications. Carbetocin, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a K_i of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (K_i=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research. Carbetocin can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-P5479

EE epitope	Peptides	Others
EE epitope is a biological active peptide. (This peptide is a 314 to 319 amino acids fragment of the middle T antigen of mouse polymavirus. Glu-Glu epitope peptide is widely used as an epitope tag.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)

HY-P5429

DNA-PK Substrate	Peptides	Others
DNA-PK Substrate is a biological active peptide. (A substrate for DNA-dependent protein kinase (DNA-PK), phosphorylation. DNA-PK is essential for the repair of DNA double-strand breaks. This peptide corresponding to 11–24 amino acids of human p53 with threonine 18 and serine 20 changed to alanine is used as a substrate for the assay of DNA-PK activityPyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)

Cat. No.	Product Name	Target	Research Area

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

HY-P990088

Sotiburafusp alfa	VEGFR PD-1/PD-L1	Cardiovascular Disease
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker ¹⁰¹GGSGGSGGSGGSGGS ¹¹⁵ to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor .

Cat. No.	Compare	Product Name	Species	Source

HY-P71340

	STUB1 Protein, Human 2 Publications Verification E3 Ubiquitin-Protein Ligase CHIP; Antigen NY-CO-7; CLL-Associated Antigen KW-8; Carboxy terminus of Hsp70-Interacting Protein; STIP1 Homology and U Box-Containing Protein 1; STUB1; CHIP	Human	E. coli
	STUB1 protein is an E3 ubiquitin protein ligase that cooperates with ATXN3 to regulate ubiquitin chain length on substrates and prevent chain extension. It ubiquitinates NOS1 through Hsp70/Hsp40 and regulates chaperone complexes (Hsp70, Hsc70, Hsp90). STUB1 Protein, Human is the recombinant human-derived STUB1 protein, expressed by E. coli , with tag free. The total length of STUB1 Protein, Human is 303 a.a., with molecular weight of ~33.0 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-144012A

16:0 PEG350 PE DPPE-PEG350; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium		Pegylated Lipids
16:0 PEG350 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012B

16:0 PEG550 PE DPPE-PEG550; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium		Pegylated Lipids
16:0 PEG550 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012C

16:0 PEG750 PE DPPE-PEG750; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium		Pegylated Lipids
16:0 PEG750 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013A

18:0 mPEG350 PE ammonium DSPE-mPEG350 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium		Pegylated Lipids
18:0 mPEG350 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013B

18:0 mPEG550 PE ammonium DSPE-mPEG550 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium		Pegylated Lipids
18:0 mPEG550 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013C

18:0 mPEG750 PE ammonium DSPE-mPEG750 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium		Pegylated Lipids
18:0 mPEG750 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012D

16:0 PEG1000 PE DPPE-PEG1000; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium		Pegylated Lipids
16:0 PEG1000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012E

16:0 PEG3000 PE DPPE-PEG3000; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium		Pegylated Lipids
16:0 PEG3000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012H

16:0 PEG5000 PE DPPE-PEG5000; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium		Pegylated Lipids
16:0 PEG5000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013D

18:0 mPEG1000 PE ammonium DSPE-mPEG1000 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium		Pegylated Lipids
18:0 mPEG1000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013E

18:0 mPEG3000 PE ammonium DSPE-mPEG3000 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium		Pegylated Lipids
18:0 mPEG3000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013H

18:0 mPEG5000 PE ammonium DSPE-mPEG5000 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium		Pegylated Lipids
18:0 mPEG5000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155924

14:0 PEG350 PE DMPE-PEG350; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium		Pegylated Lipids
14:0 PEG350 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155925

14:0 PEG550 PE DMPE-PEG550; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium		Pegylated Lipids
14:0 PEG550 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155926

14:0 PEG750 PE DMPE-PEG750; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium		Pegylated Lipids
14:0 PEG750 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155927

14:0 PEG1000 PE DMPE-PEG1000; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium		Pegylated Lipids
14:0 PEG1000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155928

14:0 PEG3000 PE DMPE-PEG3000; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium		Pegylated Lipids
14:0 PEG3000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155929

14:0 PEG5000 PE DMPE-PEG5000; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium		Pegylated Lipids
14:0 PEG5000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155930

18:1 PEG350 PE DOPE-PEG350; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium		Pegylated Lipids
18:1 PEG350 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155931

18:1 PEG550 PE DOPE-PEG550; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium		Pegylated Lipids
18:1 PEG550 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155932

18:1 PEG1000 PE DOPE-PEG1000; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium		Pegylated Lipids
18:1 PEG1000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155933

18:1 PEG3000 PE DOPE-PEG3000; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium		Pegylated Lipids
18:1 PEG3000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155934

18:1 PEG5000 PE DOPE-PEG5000; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium		Pegylated Lipids
18:1 PEG5000 PE is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

terminus

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Oligonucleotides

Natural
Products